Chiesi USA
CRTX
Performance
About Chiesi USA
Chiesi USA is a pharmaceutical company focused on developing and commercializing therapies to improve patient outcomes. The company emphasizes a future‑focused approach to care, with initiatives across therapeutic areas and a commitment to sustainability and collaboration with providers. Based in Cary, North Carolina, it operates to advance innovations in patient care, including rare diseases, neonatology, critical care, and respiratory health through its U.S. activities and partnerships.
Recent News
Makary Resigns, BMS Bets $15B on China R&D, and Regenxbio Wins Phase 3 in Duchenne – This Week in Biotech #100
Pharma and Biotech M&As 2026 Deal Watcher
In Chiesi’s Biggest M&A Deal yet, Pharma Buys HAE Company KalVista
Intellia’s In‑Vivo CRISPR Therapy Clears Phase 3, Prompting $1.9 B Chiesi Deal
Angelini Inks $4.1B Catalyst Buy to Enter US Rare Disease Market
Infex Chases After Insmed with Bronchiectasis Trial Win
Chiesi to Acquire KalVista for $1.9 B, Adding First Oral HAE Therapy
Chiesi Group to Acquire KalVista Pharmaceuticals for ~$1.9B
CVC and GBL Unveil €10.7 Bn Take‑Private Offer for Recordati
Sustainability in Asthma and COPD Drug Development with Chiesi’s Diego Ardigò — Episode 259
Regulatory Actions for June 8, 2026
Chiesi Snaps up KalVista for $1.9B, Betting Big on Rare Disease Med Ekterly